Last reviewed · How we verify
NCT07180121: CaRe
Information Needs and Supportive Rehabilitation Over Time in Patients Undergoing Cystectomy in Bladder Cancer
trial in Bladder Cancer in 200 participants. Enrolling by invitation.
31 December 2026
Quick facts
| Lead sponsor | Linkoeping University |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 19 September 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Sweden |
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
Linkoeping University
Who can join
Adults 18 to 100, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bladder cancer is one of the diseases that can affect the urinary tract. Globally, it is the tenth most common cancer, with an incidence rate of 9.5 per 100,000 persons per year for men and 2.4 for women. In Sweden, approximately 3,200 patients are diagnosed annually. It predominantly affects the elderly population over 70 years old. Men are more frequently affected, and bladder cancer is now the fourth most common cancer among men in Sweden. Radical cystectomy is the gold standard treatment for non-metastatic muscle-invasive bladder cancer. The operation involves the removal of the bladder. Most patients are treated with chemotherapy beforehand. A new urinary diversion is created using the small intestine, with the ileal conduit being the most common type. The ureters are connected to the segment of the small intestine, which is then brought out as a stoma on the abdominal wall. Urine will now be collected in a stoma bag. The operation is extensive and can be performed using open or robot-assisted laparoscopic techniques. The average hospital stay for patients undergoing surgery in Sweden is approximately fifteen days. For patients undergoing cystectomy, their future life is affected by both external and internal physical changes that they need to adapt to. The external physical change with a stoma alters their body appearance, and self-care needs to be performed for the rest of their lives. Self-care, symptoms, and complications can limit patients in their daily lives and negatively impact their social life. The internal physical change affects the internal genital organs and can impact sexual function. This can limit patients' sexual and intimate life. Receiving a cancer diagnosis is overwhelming. From this moment, a process begins for each individual that involves receiving and absorbing information about the disease and surgery, treatment, and future life. Patients generally have difficulty remembering and absorbing information given during healthcare visits. A cancer diagnosis creates anxiety and is frightening, further impacting what patients remember afterward. Information needs arise when there is a gap between the available information and knowledge compared to what is needed. The patient group feels that their information needs are not met by healthcare personnel during the process from diagnosis to surgery and the immediate time afterward. Self-care is defined as a process to maintain and uphold health through health-promoting activities and strategies to manage illness. It is a fundamental part of patients' treatment and affects the conditions for adapting to their new everyday life and promotes independent living. Well-functioning self-care contributes to higher health-related quality of life, faster recovery after surgery, reduced risk of complications, less utilization of hospital care leading to reduced healthcare costs, and longer survival. Self-care is an umbrella term that includes self-monitoring and self-management. Self-monitoring involves independently monitoring, interpreting, and assessing whether symptoms require action or contact with healthcare personnel. Self-management is necessary for recovery to manage health problems with troublesome symptoms that arise. Self-efficacy involves confidence in one's own ability and is significant for adherence to self-care. Empowerment focuses on the ability and responsibility for choices to achieve one's goals and gain control over one's own life. Health literacy is linked to literacy and encompasses a person's knowledge, motivation, and competence to access, understand, assess, and make decisions based on health-related information. Together, these concepts contribute to patients' ability to adapt to their cancer diagnosis and improve their ability to manage treatment-related behavioral changes. Needs arising from illness and treatment vary over time. They can arise before, during, and sometimes long after the treatment. Continuous, structured mapping of problem areas facilitates the identification of individualized interventions. Cancer rehabilitation promotes health and quality of life and is fundamental to preventing disability, maintaining or regaining previous physical abilities. The level of intervention and education depends on the extent and complexity of the needs and must consider health literacy. Scientific Purpose of the Project To explore information needs, health, and supportive rehabilitation in patients with bladder cancer undergoing radical cystectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07180121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Linkoeping University trials
Trials by the same sponsor.
- NCT07494422 — A Path to Prevention of Elder Abuse in Long-term Care. Prevalence Study Among Staff in Long-term Care. · not yet recruiting
- NCT07485439 — Self-inspired & Tailored Autism Movement With Phystic App · NA · enrolling by invitation
- NCT07391540 — ICBT for Psychological Symptoms Related to Economy · NA · recruiting
- NCT07181213 — Genetic Predisposition to High Blood Pressure · NA · enrolling by invitation
- NCT07312136 — MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07180121 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Linkoeping University
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07180121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing